Literature DB >> 10807049

The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer.

O Haus1.   

Abstract

The paper presents a review of data on the localization of interferons (IFNs) and IFN system genes and their relationship with human diseases, mainly cancer. Genes of interferon system proteins are located at the sites of breakpoints of the structural chromosome aberrations in cancer. Thus, any of them are rearranged or translocated in various tumor types. As the activity of these genes plays a role in cancer development, their rearrangements may be one of the crucial points in the pathogenesis of some cancer types. Besides, they also take part in organism immunity against viral infections. Transfection experiments with IFN system genes have proved the influence of these genes on cancer behavior and may serve as a basis for clinical gene therapy. IFN-alpha and IFN-beta genes are located at 9p21-22, the site of frequent homozygotic deletions in cancer. Their loss sensitizes cells to the growth inhibitory actions of exogenous IFNs. The IFN-gamma gene, a representative of class II genes, is located at 12q24.1. Transfection of class II IFNs genes to cancer cell lines causes cell proliferation arrest and augments the expression of HLA antigens, which may be clinically useful in stimulating the immune destruction of tumor cells. The interferon regulatory factor 1 (IRF-1) gene is located at 5q31, the site of common deletions in myelodysplastic syndromes (MDS) and secondary leukemias. The loss of heterozygosity of this gene was found in MDS, which proves that IRF-1 may be a tumor suppressor. A transfection of its gene causes neoplastic transformation arrest. The double-stranded RNA-activated protein kinase (PKR) gene is located at 2p21-22, a region which is frequently rearranged in leukemia. Transfection of a wild type PKR gene reverses neoplastic transformation caused by transfection of a mutated PKR gene, proving that PKR acts as a dominant negative cancer suppressor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807049

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  10 in total

1.  Synthesis and expression of recombinant interferon alpha-5 gene in tobacco chloroplasts, a non-edible plant.

Authors:  Muhammad Sarwar Khan; Farwa Nurjis
Journal:  Mol Biol Rep       Date:  2011-09-22       Impact factor: 2.316

2.  p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs.

Authors:  Katerina I Leonova; Leonid Brodsky; Brittany Lipchick; Mahadeb Pal; Liliya Novototskaya; Alex A Chenchik; Ganes C Sen; Elena A Komarova; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

Review 3.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

4.  Transcriptional activity of genes encoding interferon gamma (IFNgamma) and its receptor assessed in peripheral blood mononuclear cells in patients with cardiac syndrome X.

Authors:  Jozefa Dabek; Andrzej Kulach; Tadeusz Wilczok; Urszula Mazurek; Daniel Jakubowski; Zbigniew Gasior
Journal:  Inflammation       Date:  2007-06-02       Impact factor: 4.092

Review 5.  Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action.

Authors:  M A García; J Gil; I Ventoso; S Guerra; E Domingo; C Rivas; M Esteban
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

6.  Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Authors:  G R Simpson; A Horvath; N E Annels; T Pencavel; S Metcalf; R Seth; P Peschard; T Price; R S Coffin; H Mostafid; A A Melcher; K J Harrington; H S Pandha
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

Review 7.  Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.

Authors:  Janaina Fernandes
Journal:  Biomark Cancer       Date:  2016-07-28

8.  Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Authors:  Olga V Matveeva; Zong S Guo; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

Review 9.  Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.

Authors:  Tasha Hughes; Robert S Coffin; Caroline E Lilley; Rafael Ponce; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2014-01-15

10.  Oncolysis by paramyxoviruses: preclinical and clinical studies.

Authors:  Olga V Matveeva; Zong S Guo; Vyacheslav M Senin; Anna V Senina; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-10-21       Impact factor: 7.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.